COMPASS Pathways Phase 3 Results: What They Mean for FDA Approval
About This Video
COMPASS Pathways released Phase 3 trial data for COMP360 (synthetic psilocybin) for treatment-resistant depression in mid-2025, making it the most advanced psilocybin compound in the FDA approval pipeline. This presentation from COMPASS researchers explains what the Phase 3 data show, how the trial was designed, and what the path to FDA approval looks like from here.
The results are positive but more nuanced than Phase 2 data suggested. The 25mg dose arm showed statistically significant and clinically meaningful response rates at 3 and 6 weeks. The 10mg arm showed a trend but did not reach statistical significance as a standalone treatment. The key regulatory question — whether FDA will require a REMS (Risk Evaluation and Mitigation Strategy) program requiring administration in certified clinical settings — appears likely to be answered yes, which will shape how the drug is prescribed and administered if approved.
Key Takeaways
- COMP360 25mg showed statistically significant response in treatment-resistant depression at 3 and 6 weeks in Phase 3 trials.
- FDA approval would likely require a REMS program — administration in certified clinical settings only, not standard outpatient pharmacy dispensing.
- If approved, COMP360 would be the first FDA-approved psychedelic, creating a regulatory framework that could influence how other compounds are treated.
- The COMPASS model uses a single dose (not repeated doses) of synthetic psilocybin in a clinical session — different from therapeutic service center models in Oregon and Colorado.
- Phase 3 completion does not mean immediate approval — a New Drug Application (NDA) must be filed and reviewed, a process that typically takes 1–2 years.
Dive Deeper
Continue exploring this topic on LearnShrooms: